Loading clinical trials...
Loading clinical trials...
A Six Month Double-Blind, Placebo-Controlled Trial Followed by Six Month Open-Label Study of the Early Administration of Alendronate on Prevention of Bone Loss After Hip Fracture.
To determine whether administration of Alendronate early is more effective than late in the prevention of osteoporosis following a hip fracture
Age
55 - No limit years
Sex
ALL
Healthy Volunteers
No
Mcgill University Health center
Montreal, Quebec, Canada
Start Date
January 1, 2003
Completion Date
April 1, 2007
Last Updated
April 12, 2007
10
Estimated participants
Alendronate
DRUG
Lead Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07281586